This identifies PRMT7 as a key regulator of PTEN, opening new avenues for developing therapeutic strategies aimed at enhancing bone regeneration and treating bone-related disorders, such as osteopenia and osteoporosis. This evidence concerns the gene PTEN and Osteopenia.